Naturwissenschaften

, Volume 90, Issue 11, pp 485–494 | Cite as

Light, timing of biological rhythms, and chronodisruption in man

  • Thomas C. Erren
  • Russel J. Reiter
  • Claus Piekarski
Review

Abstract

This paper reviews abundant evidence suggesting that causes and course of aging and cancers can be considered as being both light- and rhythm-related. We define chronodisruption as a relevant disturbance of orderly biological rhythms over days and seasons and years in man. Light is the primary external mediator and melatonin a primary internal intermediary of such disturbances, which can result in earlier deaths via premature aging and cancers. We conclude that experimental and epidemiological research can provide further insights into common denominators of these chronic processes and may offer novel and uniform targets for prevention.

References

  1. Agrawal A, Chandra D, Kale RK (2001) Radiation induced oxidative stress. II. Studies in liver as a distant organ of tumor bearing mice. Mol Cell Biochem 224:9–17CrossRefPubMedGoogle Scholar
  2. Armstrong SM, Redman JR (1991) Melatonin: a chronobiotic with antiaging properties. Med Hypotheses 34:300–309PubMedGoogle Scholar
  3. Auvinen A, Pukkala E, Blettner M (1999) Risk of breast cancer among female airline cabin attendants. Large European studies are now carried. BMJ 318:125–126Google Scholar
  4. Ballard T, Lagorio S, De Angelis G, Verdecchia A (2000) Cancer incidence and mortality among flight personnel: a meta-analysis. Aviat Space Environ Med 71:216–224PubMedGoogle Scholar
  5. Beck-Friis J, Rosen D von, Kjellman BF, Ljunggren JG, Wetterberg L (1984) Melatonin in relation to body measures, sex, age, season and the use of drugs in patients with major affective disorders and healthy subjects. Psychoneuroendocrinology 9:261–277CrossRefGoogle Scholar
  6. Bellingham J, Foster RG (2002) Opsins and mammalian photoentrainment. Cell Tiss Res 309:57–71CrossRefGoogle Scholar
  7. Berson DM, Dunn FA, Takao M (2002) Phototransduction by retinal ganglion cells that set the circadian clock. Science 295:1070–1073PubMedGoogle Scholar
  8. Blackshaw S, Snyder SH (1999) Encephalopsin: a novel mammalian extraretinal opsin discretely localized in the brain. J Neurosci 19:3681–3690PubMedGoogle Scholar
  9. Blask DE (1997) Systemic, cellular, and molecular aspects of melatonin action on experimental breast carcinogenesis. In: Stevens RG, Wilson BW, Anderson LE, (eds.) The melatonin hypothesis: breast cancer and the use of electric power. Battelle, Columbus, Ohio, pp 189–230Google Scholar
  10. Blask DE (2001) An overview of the neuroendocrine regulation of experimental tumor growth by melatonin and its analogues and the therapeutic use of melatonin in oncology. In: Bartsch C, Bartsch H, Blask, DE, Cardinali DP, Hrushesky WJM, Mecke D (eds) The pineal gland and cancer. Springer, Berlin Heidelberg New York, pp 309–342Google Scholar
  11. Blask DE, Sauer LA, Dauchy RT (2002a) Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2:113–132PubMedGoogle Scholar
  12. Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC (2002b) Light during darkness, melatonin suppression and cancer progression. Neuroendocrinol Lett 23(suppl 2):52–56PubMedGoogle Scholar
  13. Boice JD Jr, Blettner M, Auvinen A (2000) Epidemiologic studies of pilots and aircrew. Health Phys 79:576–584PubMedGoogle Scholar
  14. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E, Rollag MD (2001) Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 21:6405–6412PubMedGoogle Scholar
  15. Brzezinski A (1997) Melatonin in humans. N Engl J Med 336:186–195PubMedGoogle Scholar
  16. Coleman MP, Reiter RJ (1992) Breast cancer, blindness and melatonin. Eur J Cancer 28:501–503PubMedGoogle Scholar
  17. Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, Emens JS, Klein T, Rizzo JF III (1995) Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med 332:6–11PubMedGoogle Scholar
  18. Darwin C (1859) On the ORIGIN OF SPECIES. Chapter IV: Natural selection; or the survival of the fittestGoogle Scholar
  19. Dauchy RT, Sauer LA, Blask DE, Vaughan GM (1997) Light contamination during the dark phase in “photoperiodically controlled” animal rooms: effect on tumor growth and metabolism in rats. Lab Anim Sci 47:511–518PubMedGoogle Scholar
  20. Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562PubMedGoogle Scholar
  21. Erren TC (2001) A meta-analysis of epidemiologic studies of electric and magnetic fields and breast cancer in women and men. Bioelectromagnetics Suppl 5:S105–S119CrossRefGoogle Scholar
  22. Erren TC (2002) Does light cause internal cancers? The problem and challenge of an ubiquitous exposure. Neuroendocrinol Lett 23(suppl 2):61–70CrossRefGoogle Scholar
  23. Erren TC, Piekarski C (1999) Does winter darkness in the Arctic protect against cancer? The melatonin hypothesis revisited. Med Hypotheses 53:1–5CrossRefPubMedGoogle Scholar
  24. Erren TC, Bjerregaard P, Cocco P, Lerchl A, Verkasalo P (2001) Re:”Invited commentary: electromagnetic fields and cancer in railway workers. Am J Epidemiol 154:977–979Google Scholar
  25. Feychting M, Osterlund B, Ahlbom A (1998) Reduced cancer incidence among the blind. Epidemiology 9:490–494PubMedGoogle Scholar
  26. Freedman MS, Lucas RJ, Soni B, Schantz M von, Munoz M, David-Gray Z, Foster R (1999) Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. Science 284:502–504PubMedGoogle Scholar
  27. Gillette MU, Tischkau SA (1999) Suprachiasmatic nucleus: the brain’s circadian clock. Rec Progr Harm Res 54:33–58Google Scholar
  28. Glickman G, Levin R, Brainard GC (2002) Ocular input for human melatonin regulation: relevance to breast cancer. Neuroendocrinol Lett 23(suppl 2):17–22Google Scholar
  29. Hahn RA (1991) Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2:208–210PubMedGoogle Scholar
  30. Halliwell B, Aruoma OI (1993) DNA and free radicals. Ellis Harwood, LondonGoogle Scholar
  31. Hankins MW, Lucas RJ (2002) The primary visual pathway in humans is regulated according to long-term light exposure through the action of a nonclassical photopigment. Curr Biol 12:191–198PubMedGoogle Scholar
  32. Hansen J (2001a) Increased breast cancer risk among women who work predominantly at night. Epidemiology 12:74–77CrossRefPubMedGoogle Scholar
  33. Hansen J (2001b) Light at night, shiftwork, and breast cancer risk. J Natl Cancer Inst 93:1513–1515CrossRefPubMedGoogle Scholar
  34. Härma M, Laitinen J, Partinen M, Suvanto S (1994) The effect of four-day round trip flights over 10 time zones on the circadian variation of salivary melatonin and cortisol in airline flight attendants. Ergonomics 37:1479–1489PubMedGoogle Scholar
  35. Harman D (1992) Free radical theory of aging. Mutat Res 275:257–266CrossRefPubMedGoogle Scholar
  36. Hatonen T, Alila-Johansson A, Mustanoja S, Laakso ML (1999) Suppression of melatonin by 2000-lux light in humans with closed eyelids. Biol Psychiatry 46:827–831CrossRefPubMedGoogle Scholar
  37. Hattar S, Liao HW, Takao M, Berson DM, Yau KW (2002) Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 295:1065–1070PubMedGoogle Scholar
  38. Hurd MW, Ralph MR (1998) The significance of circadian organization for longevity in the golden hamster. J Biol Rhythms 13:430–436PubMedGoogle Scholar
  39. Jean-Louis G, Kripke DF, Cole RJ, Elliot JA (2000) No melatonin suppression by illumination of popliteal fossae or eyelids. J Biol Rhythms 15:265–269PubMedGoogle Scholar
  40. Karbownik M, Reiter RJ (2000) Antioxidative effects of melatonin in protection against cellular damage by ionizing radiation. Proc Soc Exp Biol Med 225:9–22CrossRefPubMedGoogle Scholar
  41. Karbownik M, Lewinski A, Reiter RJ (2001) Anticarcinogenic actions of melatonin that involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 33:735–753CrossRefPubMedGoogle Scholar
  42. Kauppila A, Kivelä A, Pakarinen A, Vakkuri O (1987) Inverse seasonal relationship between melatonin and ovarian activity in humans in a region with strong seasonal contrast in luminosity. J Clin Endocrinol Metab 65:823–828PubMedGoogle Scholar
  43. Kivelä A, Kauppila A, Ylostalo P, Vakkuri O, Leppaluoto J (1988) Seasonal, menstrual and circadian secretions of melatonin, gonadotropins and prolactin in women. Acta Physiol Scand 132:321–327PubMedGoogle Scholar
  44. Klerman EB, Zeitzer JM, Duffy JF, Khalsa SB, Czeisler CA (2001) Absence of an increase in the duration of the circadian melatonin secretory episode in totally blind human subjects. J Clin Endocrinol Metab 86:3166–3170PubMedGoogle Scholar
  45. Klerman EB, Shanahan TL, Brotman DJ, Rimmer DW, Emens JS, Rizzo JF III, Czeisler CA (2002) Photic resetting of the human circadian pacemaker in the absence of conscious vision. J Biol Rhythms 17:548–555CrossRefPubMedGoogle Scholar
  46. Kliukiene J, Tynes T, Andersen A (2001). Risk of breast cancer among Norwegian women with visual impairment. Br J Cancer 84:397–399CrossRefPubMedGoogle Scholar
  47. Laakso ML, Porkka-Heiskanen T, Alila A, Stenberg D, Johansson G (1994) Twenty-four-hour rhythms in relation to the natural photoperiod: a field study in humans. J Biol Rhythms 9:283–293PubMedGoogle Scholar
  48. Levine ME, Milliron AN, Duffy LK (1994) Diurnal and seasonal rhythms of melatonin, cortisol and testosterone in interior Alaska. Arctic Med Res 53:25–34PubMedGoogle Scholar
  49. Lockley SW, Skene DJ, Arendt J, Tabandeh H, Bird AC, Defrance R (1997) Relationship between melatonin rhythms and visual loss in the blind. J Clin Endocrinol Metab 82:3763–3770PubMedGoogle Scholar
  50. Lucas RJ, Freedman MS, Munoz M, Garcia-Fernandez JM, Foster RG (1999) Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. Science 284:505–507PubMedGoogle Scholar
  51. Lucas RJ, Douglas RH, Foster RG (2001) Characterization of an ocular photopigment capable of driving pupillary constriction in mice. Nat Neurosci 4:621–626PubMedGoogle Scholar
  52. Lucas RJ, Hattar S, Takao M, Berson DM, Foster RG, Yau KW (2003) Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice. Science 299:245–247CrossRefPubMedGoogle Scholar
  53. Lynge E (2001) Commentary: cancer in the air. Int J Epidemiol 30:830–832CrossRefPubMedGoogle Scholar
  54. Martikainen H, Tapanainen J, Vakkuri O, Leppaluoto J, Huhtaniemi I (1985) Circannual concentrations of melatonin, gonadotrophins, prolactin and gonadal steroids in males in a geographical area with a large annual variation in daylight. Acta Endocrinol 109:446–450PubMedGoogle Scholar
  55. Mawson AR (1998) Breast cancer in female flight attendants. Lancet 352:626PubMedGoogle Scholar
  56. Miyamoto Y, Sancar A (1998) Vitamin B2-based blue-light photoreceptors in the retinohypothalamic tract as the photoactive pigments for setting the circadian clock in mammals. Proc Natl Acad Sci USA 95:6097–6102PubMedGoogle Scholar
  57. Panda S, Sato TK, Castrucci AM, Rollag MD, DeGrip WJ, Hogenesch JB, Provencio I, Kay SA (2002) Melanopsin (Opn4) requirement for normal light-induced circadian phase shifting. Science 298:2213–2216CrossRefPubMedGoogle Scholar
  58. Panzer A, Viljoen M (1997) The validity of melatonin as an oncostatic agent. J Pineal Res 22:184–202PubMedGoogle Scholar
  59. Poole C (2002) The darkness at the end of the tunnel: summary and evaluation of an international symposium on light, endocrine systems and cancer. Neuroendocrinol Lett 23(suppl 2):71–78PubMedGoogle Scholar
  60. Portier CJ (2000) Decisions about environmental health risks: what are the key questions and how does this apply to melatonin? In: Erren TC, Piekarski C (eds) Low frequency EMF, visible light, melatonin and cancer: international symposium, 4–5 May 2000, University of Cologne. Zbl Arbeitsmed 2000 50:298–314. Available as summaries at http://www.uni-koeln.de/symposium2000/
  61. Portier CJ (2002) Comments on the international symposium on light, endocrine systems and cancer. Neuroendocrinol Lett 23(suppl 2):79–81Google Scholar
  62. Provencio I, Cooper HM, Foster RG (1998) Retinal projections in mice with inherited retinal degeneration: implications for circadian photoentrainment. J Comp Neurol 395:417–439CrossRefPubMedGoogle Scholar
  63. Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD (2000) A novel human opsin in the inner retina. J Neurosci 20:600–605PubMedGoogle Scholar
  64. Provencio I, Rollag MD, Castrucci AM (2002) Photoreceptive net in the mammalian retina: this mesh of cells may explain how some blind mice can still tell day from night. Nature 415:493Google Scholar
  65. Pukkala E, Verkasalo PK, Ojarno M, Rudanko S-L (1999) Visual impairment and cancer: a population-based cohort study in Finland. Cancer Causes Control 10:13–20CrossRefPubMedGoogle Scholar
  66. Pukkala E, Aspholm R, Auvinen A, Eliasch H, Gundestrup M, Haldorsen T, Hammar N, Hrafnkelsson J, Kyyronen P, Linnersjo A, Rafnsson V, Storm H, Tveten U (2002) Incidence of cancer among Nordic airline pilots over five decades: occupational cohort study. BMJ 325:567–571CrossRefPubMedGoogle Scholar
  67. Reiter RJ (1991) Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 79:C153–158PubMedGoogle Scholar
  68. Reiter RJ (1993) The melatonin rhythm: both a clock and a calendar. Experientia 49:654–664PubMedGoogle Scholar
  69. Reiter RJ (1999) Oxidative damage to nuclear DNA: amelioration by melatonin. Neuroendocrinol Lett 20:145–150PubMedGoogle Scholar
  70. Reiter RJ (2002) Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuroendocrinol Lett 23(suppl 2):9–13Google Scholar
  71. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Lopez-Burillo S (2002) Melatonin, longevity and health in the aged: an assessment. Free Radic Res 36:1323–1329CrossRefPubMedGoogle Scholar
  72. Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418:935–941CrossRefPubMedGoogle Scholar
  73. Rothman KJ (1976) Causes. Am J Epidemiol 104:587–592PubMedGoogle Scholar
  74. Ruby NF, Brennan TJ, Xie X, Cao V, Franken P, Heller HC, O’Hara BF (2002) Role of melanopsin in circadian responses to light. Science 298:2211–2213CrossRefPubMedGoogle Scholar
  75. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM (1986) Human melatonin production decreases with age. J Pineal Res 3:379–388PubMedGoogle Scholar
  76. Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H (1992) Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. J Clin Endocrinol Metab 75:127–134PubMedGoogle Scholar
  77. Sanchez-Barcelo EJ, Cos S, Fernndez R, Mediavilla MD (2003) International congress on hormonal steroids and hormones and cancer: melatonin and mammary cancer: a short review. Endocr Relat Cancer 10:153–159PubMedGoogle Scholar
  78. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA (2001) Rotating night shifts and risk of breast cancer in the Nurses’ Health Study. J Natl Cancer Inst 93:1563–1568PubMedGoogle Scholar
  79. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA (2003) Night-shift work and risk of colorectal cancer in the Nurses’ Health Study. J Natl Cancer Inst 95:825–828CrossRefPubMedGoogle Scholar
  80. Schroedinger E (1948) What is life? The physical aspects of the living cell. Cambridge University Press, Cambridge, pp 69, 75Google Scholar
  81. Skene DJ, Swaab DF (2003) Melatonin rhythmicity: effect of age and Alzheimer’s disease. Exp Gerontol 38:199–206CrossRefPubMedGoogle Scholar
  82. Skene DJ, Lockley SW, Arendt J (1999) Use of melatonin in the treatment of phase shift and sleep disorders. Adv Exp Med Biol 467:79–84PubMedGoogle Scholar
  83. Soni BG, Foster RG (1997) A novel and ancient vertebrate opsin. FEBS Lett 406:279–283PubMedGoogle Scholar
  84. Soni BG, Philp AR, Foster RG, Knox BE (1998) Novel retinal photoreceptors. Nature 394:27–28PubMedGoogle Scholar
  85. Stevens RG (1987) Electric power use and breast cancer: a hypothesis. Am J Epidemiol 125:556–561PubMedGoogle Scholar
  86. Stevens RG (2002) Lighting during the day and night: possible impact on risk of breast cancer. Neuroendocrinol Lett 23 Suppl 2:57–60Google Scholar
  87. Stevens RG, Rea MS (2001) Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 12:279–287CrossRefGoogle Scholar
  88. Stevens RG, Davis S, Thomas DB, Anderson LE, Wilson BW (1992) Electric power, pineal function, and the risk of breast cancer. FASEB J 6:853–860PubMedGoogle Scholar
  89. Stokkan K-A, Reiter RJ (1994) Melatonin rhythms in Arctic urban residents. J Pineal Res 16:33–36PubMedGoogle Scholar
  90. Tan DX, Poeggeler B, Reiter RJ, Chen LD, Manchester LC, Barlow-Walden LR (1993) The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett 70:65–71PubMedGoogle Scholar
  91. Thapan K, Arendt J, Skene DJ (2001) An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans. J Physiol 535:261–267PubMedGoogle Scholar
  92. Thresher RJ, Vitaterna MH, Miyamoto Y, Kazantsev A, Hsu DS, Petit C, Selby CP, Dawut L, Smithies O, Takahashi JS, Sancar A (1998) Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses. Science 282:1490–1494CrossRefPubMedGoogle Scholar
  93. Tynes T, Hannevik M, Andersen A, Vistnes AI, Haldorsen T (1996) Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control 7:197–204PubMedGoogle Scholar
  94. Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko S-L (1999) Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br J Cancer 80:1459–1460CrossRefPubMedGoogle Scholar
  95. Vijayalaxmi, Thomas CR, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575–2601CrossRefPubMedGoogle Scholar
  96. Wartenberg D, Stapleton CP (1998) Risk of breast cancer is also increased among retired US female airline cabin attendants. BMJ 316:1902Google Scholar
  97. Wetterberg L, Eberhard G, Knorring L von, Kohan MA, Ylipää E, Rutz W, Bratlid T, Lacoste V, Thompson C, Yoneda H, Rosenthal NE, McGuire M, Polleri A, Freedman M, Morton DJ, Redman J, Berigannaki JD, Shapiro C, Driver H, Yuwiler A (1993) The influence of age, sex, height, weight, urine volume and latitude on melatonin concentrations in urine from normal subjects: a multinational study. In: Wetterberg L (ed) Light and biological rhythms in man. Pergamon, Oxford, pp 275–286Google Scholar
  98. Wetterberg L, Bratlid T, Knorring L von, Eberhard G, Yuwiler A (1999a) A multinational study of the relationships between nighttime urinary melatonin production, age, gender, body size, and latitude. Eur Arch Psychiatr Clin Neurosci 249:256–262CrossRefGoogle Scholar
  99. Wetterberg L, Bergiannaki JD, Paparrigopoulos T, Knorring L von, Eberhard G, Bratlid T, Yuwiler A (1999b) Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 24:209–226CrossRefPubMedGoogle Scholar
  100. Weydahl A, Sothern RB, Wetterberg L (1998) Seasonal variations in melatonin may modulate glycemic response to exercise. Percept Mot Skills 86:1061–1062PubMedGoogle Scholar
  101. Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CA (2000) Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 85:2189–2196PubMedGoogle Scholar
  102. Zisapel N (2001) Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 15:311–328PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Thomas C. Erren
    • 1
  • Russel J. Reiter
    • 2
  • Claus Piekarski
    • 1
  1. 1.Institute and Polyclinic for Occupational and Social Medicine, School of Medicine and DentistryUniversity of CologneCologneGermany
  2. 2.The University of Texas Health Science CenterSan AntonioUSA

Personalised recommendations